Mindera Health and Mountaineer Biosciences Launch Subtilitas Platform for Precision Dermatology Research
核心洞察
Mindera Health (搜索) and Mountaineer Biosciences (搜索) have launched Subtilitas (搜索), a precision translational medicine platform that integrates non-invasive skin sampling with AI-driven molecular profiling for dermatology and immunology research.
The platform addresses limitations of traditional dermatologic research by capturing disease-relevant biological signals directly from skin without relying on visual assessment or invasive biopsies.
Subtilitas (搜索) enables objective, biology-driven insights for improved patient stratification, biomarker discovery, and enhanced decision-making in translational and clinical development.
Mindera Health (搜索) and Mountaineer Biosciences (搜索) announced the launch of Subtilitas (搜索), a precision translational medicine platform designed to revolutionize dermatology and immunology clinical research through molecular-level insights. The platform launched on March 18, 2026, represents a collaborative effort to address critical limitations in traditional dermatologic research methodologies.
Platform Technology and Capabilities
Subtilitas (搜索) integrates three core technologies: non-invasive skin sampling, advanced molecular profiling, and artificial intelligence/machine learning analysis. This combination enables high-resolution characterization of skin and immune diseases (搜索) by capturing disease-relevant biological signals directly from the skin surface.
The platform specifically addresses key limitations of traditional dermatologic research approaches that rely heavily on visual assessment and invasive biopsies. By eliminating the need for invasive procedures, Subtilitas (搜索) offers a more patient-friendly approach to dermatological research while maintaining scientific rigor.
"Combining Mindera Health (搜索)'s non-invasive skin transcriptomics and data science tools with Mountaineer Biosciences (搜索)' translational and clinical expertise, Subtilitas (搜索) provides the greater translational research community with a powerful, integrated solution for precision medicine in dermatology and immunology," said Tobin Dickerson, PhD, Chief Scientific Officer and Co-Founder of Mindera Health.
Clinical Applications and Research Impact
The platform enables objective, biology-driven insights that can improve patient stratification, support biomarker discovery, and enhance decision-making across translational and clinical development. Michael Howell, PhD, founder of Mountaineer Biosciences (搜索), emphasized that "Subtilitas (搜索) was developed to bridge scientific nuance with clinical execution."
Subtilitas (搜索) is positioned to enhance translational insight, improve trial efficiency, and advance personalized therapies for skin and immune diseases (搜索). The platform's molecular-level approach represents a significant advancement over traditional visual assessment methods commonly used in dermatological research.
Partnership Opportunities and Availability
The platform is available for partnership with biopharmaceutical companies, academic investigators, and clinical research organizations. This broad accessibility aims to accelerate precision medicine adoption across the dermatology and immunology research community.
Company Background
Mindera Health (搜索) operates as a CLIA and CAP certified laboratory with ISO 13485:2016 certification. The San Diego-area company utilizes proprietary dermal biomarker patches, Next-Generation Sequencing (NGS), and machine learning technologies to generate clinically validated data aimed at reducing healthcare system costs and improving patient outcomes.
Mountaineer Biosciences (搜索) specializes in translational science and clinical strategy, focusing on advancing precision medicine in dermatology and immunology. The company collaborates with biotechnology, pharmaceutical, and academic partners to accelerate biomarker discovery, translational research, and clinical development.